Form 4: Quest Diagnostics Executive Sells Shares Under 10b5-1 Plan

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics, sold a total of 1,748 shares of common stock on May 12 and 13, 2025, under a pre-arranged Rule 10b5-1 sales plan.

Summary

• Mark E. Delaney, a senior executive at Quest Diagnostics, sold shares of the company's common stock.
• The sales occurred on May 12 and May 13, 2025.
• A total of 1,748 shares were sold.
• The transactions were executed under a Rule 10b5-1 sales plan.
• On May 12, 874 shares were sold at a price of $175.72 per share.
• On May 13, 874 shares were sold at a price of $175.31 per share.
• Following these transactions, Delaney directly owns 7,498 shares of Quest Diagnostics common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to an executive's stock sale under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Executive stock sales are a common occurrence and are often related to personal financial planning rather than a reflection of the company's performance. The use of a 10b5-1 plan suggests the sales were pre-planned to avoid insider trading concerns.

Stakeholder Impact

• The stock sale by an executive could have a minor negative impact on shareholder sentiment, but the use of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Quest Diagnostics, DGX, Mark E. Delaney, stock sale, Form 4, Rule 10b5-1, insider trading